J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.
Farhad Ravandi,Stefan Faderl,Deborah A. Thomas,Jan A. Burger,Charles Koller,Guillermo Garcia-Manero,Gail Morris,Ritva Torma,Hagop M. Kantarjian,Jean Pierre J. Issa +9 more
TL;DR: It is concluded that the sequential combination of DAC and SAHA is safe and has activity in advanced leukemia.
Journal Article
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Stefan Koehrer,Jan A. Burger +1 more
TL;DR: The mechanisms of B CR activation that govern growth and survival of malignant B cells are reviewed and recent clinical trials of BCR inhibitors are summarized, with a focus on the most clinically advanced agents.
Journal ArticleDOI
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
Susan O'Brien,John C. Byrd,Peter Hillmen,Steven Coutre,Jennifer R. Brown,Paul M. Barr,Jacqueline C. Barrientos,Stephen Devereux,Tadeusz Robak,Nishitha Reddy,Thomas J. Kipps,Alessandra Tedeschi,Florence Cymbalista,Paolo Ghia,Stephen Chang,Joi Ninomoto,Danelle F. James,Jan A. Burger +17 more
TL;DR: In this integrated analysis, ibrutinib was associated with favorable PFS and OS, and high ORR regardless of prior therapies in patients with CLL, and the best outcomes following ibrUTinib discontinuation were for patients receiving ibrutsinib in earlier lines of therapy.
Journal ArticleDOI
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
Nitin Jain,Philip A. Thompson,Jan A. Burger,Alessandra Ferrajoli,Gautam Borthakur,Prithviraj Bose,Zeev Estrov,Tapan M. Kadia,Koichi Takahashi,Naveen Garg,Xuemei Wang,Rashmi Kanagal-Shamanna,Keyur P. Patel,Wanda Lopez,Ana Ayala,William Plunkett,Varsha Gandhi,Hagop M. Kantarjian,Susan O'Brien,Michael J. Keating,William G. Wierda +20 more
TL;DR: The intent was to limit chemotherapy to 3 cycles, potentially reducing short- and long-term toxicity, while increasing efficacy through the addition of ibrutinib and a more potent CD20 antibody (obinutuzumab) and achieving durable, therapy-free remission.
Journal ArticleDOI
Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.
Boyu Hu,Keyur P. Patel,Hsiang-Chun Chen,Xuemei Wang,Rajyalakshmi Luthra,Mark J. Routbort,Rashmi Kanagal-Shamanna,L. Jeffrey Medeiros,C. Cameron Yin,Zhuang Zuo,Chi Young Ok,Sanam Loghavi,Guilin Tang,Francesco Paolo Tambaro,Philip A. Thompson,Jan A. Burger,Nitin Jain,Alessandra Ferrajoli,Prithviraj Bose,Zeev Estrov,Michael J. Keating,William G. Wierda +21 more
TL;DR: Gene mutation data and concurrent clinical characteristics, such as Rai/Binet stage, fluorescence in situ hybridisation (FISH), ZAP70/CD38, karyotype and IGHV mutation, status were analysed in univariable and multivariable analyses to identify associations with TTFT.